SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.23+0.21 (+5.22%)
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
ARS Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $26.21M | $17.45M | $20.33M | $31.30M | $12.80M | $7.76M | $6.69M | $568.00K | $0 | $0 | $0 | $0 | 77.9% | +104.8% |
| Revenue under supply agreements | $7.39M | $2.74M | $901.00K | $1.15M | $323.00K | $0 | $365.00K | $0 | $0 | – | – | – | 22.0% | +2188.2% |
| Revenue under collaboration agreements [Member] | $57.00K | $2.49M | $6.86M | $55.00K | $2.59M | $210.00K | $79.53M | $1.50M | $500.00K | $0 | $0 | $0 | 0.2% | -97.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $26.21M | $17.45M | – | – | $12.80M | $7.76M | – | – | – | – | – | – | 77.9% | +104.8% |
| Rest of World [Member] | $4.08M | $2.45M | – | – | $34.00K | $0 | – | – | – | – | – | – | 12.1% | +11908.8% |
| Japan | $3.37M | – | – | – | – | – | – | – | – | – | – | – | 10.0% | – |
| Denmark | $2.99M | $2.78M | – | – | $2.88M | $210.00K | – | – | – | – | – | – | 8.9% | +3.7% |
From the segment and revenue-disaggregation notes of ARS Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.